{"url_path":"/sec/clrb/8-k/2026-05-08/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-057460-index.html","accession_number":"0001104659-26-057460","cik":"0001279704","ticker":"CLRB","issuer_name":"Cellectar Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1279704/0001104659-26-057460-index.html","primary_entity_key":"0001279704","primary_entity_name":"Cellectar Biosciences, Inc."},"word_count":319,"has_tables":true,"body_markdown":"**Item 8.01**\n**Other Events.**\n\n \n\nOn May 5, 2025, the\nCompany reported positive 12-month follow-up data from its Phase 2b CLOVER WaM clinical trial evaluating iopofosine I 131 in patients\nwith relapsed or refractory (r/r) WM. The Company announced that 83.6% Overall Response Rate (“ORR”) and 61.8% Major Response\nRate (“MRR”) were observed in the heavily pretreated population with median duration of response of 17.8 months. A summary\nof the efficacy results in the per protocol study population (n=55) is below:\n\n \n\n·ORR: 83.6%\n\n·MRR: 61.8% (primary endpoint achieved)\n\n·Median Duration of Response (DoR): 17.8 months\n(secondary endpoint achieved)\n\n·Median Progression-Free Survival (PFS): 13.5\nmonths\n\n·Very Good Partial Response/Complete Response\nRate: 14.5%\n\n·Disease Control Rate: 98.2%\n\n \n\nAdditionally, summaries of\nthe efficacy results in BTKi-exposed and BTKi-refractory subsets of the trial population are below:\n\n \n\nBTKi-Exposed Patients (n=39):\n\n \n\n·MRR: 64.1%\n\n·Median DoR: 18.2 months\n\n·Median PFS: 15.9 months\n\n \n\n \n\n \n\n \n\nBTKi-Refractory Patients\n(n=33):\n\n \n\n·MRR: 63.6%\n\n·Median DoR: 18.2 months\n\n·Median PFS: 14.8 months\n\n \n\nIn the trial, observed adverse\nevents were transient and there were no significant bleeding events and low rates of infection (<10%). Cytopenias were the most common\ntreatment-emergent adverse events. Non-hematologic toxicities were primarily low grade (Grade <2).\n\n \n\n**Forward Looking Statements**\n\n \n\nThis Report on Form 8-K\ncontains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of\n1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations,\nbut forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond\nthe Company’s control. For this reason, among others, you should not place undue reliance upon the Company’s forward looking\nstatements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order\nto reflect any event or circumstance that may arise after the date of this Report on Form 8-K."}